novel responses to Bi-doped strontium aluminum oxyfluorides.

Novel therapeutics for the treatment of leishmaniasis are of interest as the disease not only is becoming more prevalent, but drug resistance is increasing in certain regions of the world. Reported here is the use of Bi-doped strontium aluminum oxyfluoride phosphors and protease inhibitors to test inhibitory activity against cultured promastigote and effects on secreted acid phosphatase (SAP) activity. Cell viability did not significantly decrease in the presence of 50 μM anti-perovskite compounds, implying limited cytotoxicity.